W. H. Miller

897 total citations
17 papers, 723 citations indexed

About

W. H. Miller is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, W. H. Miller has authored 17 papers receiving a total of 723 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in W. H. Miller's work include Retinoids in leukemia and cellular processes (6 papers), Cancer Treatment and Pharmacology (3 papers) and Estrogen and related hormone effects (3 papers). W. H. Miller is often cited by papers focused on Retinoids in leukemia and cellular processes (6 papers), Cancer Treatment and Pharmacology (3 papers) and Estrogen and related hormone effects (3 papers). W. H. Miller collaborates with scholars based in United States, Canada and Italy. W. H. Miller's co-authors include Hideo Masui, José Baselga, John Mendelsohn, Keren Coplan, Atanasio Pandiella, Larry Norton, Ethan Dmitrovsky, Celeste Cagnazzo, Massimo Aglietta and Francesco Leone and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

W. H. Miller

17 papers receiving 700 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W. H. Miller United States 9 486 283 166 104 100 17 723
Tony DeBlasio United States 11 421 0.9× 575 2.0× 184 1.1× 153 1.5× 148 1.5× 15 1.0k
Jay Overholser United States 11 358 0.7× 439 1.6× 117 0.7× 138 1.3× 186 1.9× 16 767
Michelle D. Martin United States 9 499 1.0× 348 1.2× 88 0.5× 50 0.5× 63 0.6× 14 796
Yvette van Hensbergen Netherlands 12 348 0.7× 301 1.1× 57 0.3× 47 0.5× 129 1.3× 22 666
Cynthia S. Snyder United States 13 178 0.4× 255 0.9× 104 0.6× 29 0.3× 60 0.6× 22 733
D. Fan United States 14 359 0.7× 404 1.4× 168 1.0× 128 1.2× 97 1.0× 23 804
Daniela Kandioler-Eckersberger Austria 8 389 0.8× 220 0.8× 81 0.5× 106 1.0× 18 0.2× 11 583
Henry Koo United States 5 237 0.5× 538 1.9× 86 0.5× 156 1.5× 53 0.5× 6 731
Andreas Enns Germany 9 289 0.6× 506 1.8× 59 0.4× 33 0.3× 137 1.4× 9 889
Ami Goradia United States 8 543 1.1× 436 1.5× 151 0.9× 17 0.2× 334 3.3× 10 1.1k

Countries citing papers authored by W. H. Miller

Since Specialization
Citations

This map shows the geographic impact of W. H. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. H. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. H. Miller more than expected).

Fields of papers citing papers by W. H. Miller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. H. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. H. Miller. The network helps show where W. H. Miller may publish in the future.

Co-authorship network of co-authors of W. H. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of W. H. Miller. A scholar is included among the top collaborators of W. H. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. H. Miller. W. H. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
O’Malley, David M., Giovanni M. Bariani, Aurélien Marabelle, et al.. (2022). 546P Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158. Annals of Oncology. 33. S796–S797. 2 indexed citations
2.
O’Malley, David M., Giovanni M. Bariani, Philippe A. Cassier, et al.. (2021). 795MO Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158. Annals of Oncology. 32. S730–S731. 5 indexed citations
3.
Aglietta, Massimo, Carlo Barone, W. H. Miller, et al.. (2014). A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Annals of Oncology. 25(9). 1750–1755. 169 indexed citations
4.
Pishvaian, Michael J., Dina Sakaeva, Ruey-Kuen Hsieh, et al.. (2011). A global, multicenter phase II trial of lapatinib plus capecitabine in gastric cancer.. Journal of Clinical Oncology. 29(4_suppl). 88–88. 8 indexed citations
5.
6.
Neven, Patrick, et al.. (2009). Safety of the anti-IGF-1R antibody CP-751,871 in combination with exemestane in patients with advanced breast cancer.. Cancer Research. 69(2_Supplement). 2136–2136. 5 indexed citations
7.
Blumenschein, G. R., Fadlo R. Khuri, U. Gatzemeier, et al.. (2005). A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 23(16_suppl). LBA7001–LBA7001. 24 indexed citations
8.
Miller, W. H.. (2002). Molecular Targets of Arsenic Trioxide in Malignant Cells. The Oncologist. 7(90001). 14–19. 8 indexed citations
9.
Seiter, Karen, et al.. (1995). Pilot study of all-trans retinoic acid as post-remission therapy in patients with acute promyelocytic leukemia.. PubMed. 9(1). 15–8. 8 indexed citations
10.
Bentel, Jacqueline M., et al.. (1994). Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice.. Drug Metabolism and Disposition. 22(3). 451–458. 56 indexed citations
11.
Baselga, José, Larry Norton, Hideo Masui, et al.. (1993). Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies. JNCI Journal of the National Cancer Institute. 85(16). 1327–1333. 332 indexed citations
12.
Maslak, P., W. H. Miller, Gerwin Heller, et al.. (1993). CD2 expression and PML/RAR-alpha transcripts in acute promyelocytic leukemia [letter; comment] [see comments]. Blood. 81(6). 1666–1666. 9 indexed citations
13.
Miller, W. H. & Ethan Dmitrovsky. (1993). Retinoic acid and its rearranged receptor in the treatment of acute promyelocytic leukemia.. PubMed. 81–90. 6 indexed citations
14.
Baselga, José, W. H. Miller, Larissa Moreira Spinola de Castro Raucci, et al.. (1993). Over-expression of transforming growth factor alpha antagonizes the anti-tumorigenic but not the differentiation actions of retinoic acid in a human teratocarcinoma cell.. PubMed. 8(12). 3257–63. 11 indexed citations
15.
Dmitrovsky, Ethan, et al.. (1990). Retinoic acid causes a decline in TGF-alpha expression, cloning efficiency, and tumorigenicity in a human embryonal cancer cell line.. PubMed. 5(3). 233–9. 38 indexed citations
16.
Dmitrovsky, Ethan, Vundavalli V. Murty, W. H. Miller, et al.. (1990). Isochromosome 12p in non-seminoma cell lines: karyologic amplification of c-ki-ras2 without point-mutational activation.. PubMed. 5(4). 543–8. 26 indexed citations
17.
Ross, James G. & W. H. Miller. (1961). SOMATIC CHROMOSOMES IDENTIFIED IN THE EVER-SPORTING TYPE OF STOCK. Journal of Heredity. 52(5). 195–199. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tony DeBlasio Breakdown of academic impact, for papers by Jay Overholser Breakdown of academic impact, for papers by Michelle D. Martin Breakdown of academic impact, for papers by Yvette van Hensbergen Breakdown of academic impact, for papers by Cynthia S. Snyder Breakdown of academic impact, for papers by D. Fan Breakdown of academic impact, for papers by Daniela Kandioler-Eckersberger Breakdown of academic impact, for papers by Henry Koo Breakdown of academic impact, for papers by Andreas Enns Breakdown of academic impact, for papers by Ami Goradia
Rankless by CCL
2026